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SELECTION OF THE MONTH 
Big title: Treated HCV cirrhosis patients can have normal life expectancy  
 
Small Titles:  
HBV integration generates oncogenic chimera 
Is there a place for response-guided DAA treatment? 
Potential novel biomarker to predict beta-blocker response in cirrhosis  
Type 2 diabetes and the burden of chronic liver diseases 
 
ACUTE HEPATITIS 
Role of cytotoxic CD8 T lymphocytes (CTLs) 
2 
 
Acute hepatitis can be a result of CTL action but factors that limit CTL-mediated liver 
injury are poorly understood. Vo et al. addressed this question using elegant strategies 
aiming to investigate the role of regulation of T cell death, regulation of CTL function 
and T cell inhibitory molecules, independently of TCR affinity, T cell help and antigen 
dose. In the setting of high-level persistent antigen expression in the liver, the degree 
and duration. Their results show that liver damage is predominantly regulated by genes 
controlling the function of effector cells rather than those affecting T cell lifespan. 
Persistence of liver damage is actually limited by functional T cell exhaustion. These 
data suggest that immunotherapies aimed at increasing the number of CTLs in 
patients with liver disease should be combined with strategies that enhance T 
cell effector function and interfere with T cell exhaustion. 
 
LIVER REGENERATION 
Human embryonic stem cell (hESC) utilization 
Hepatocytes differentiated from human embryonic stem cells (hESCs) might be a 
response brought to the shortage of primary hepatocytes for clinical use and drug 
development. Touboul et al. hypothesized that the functionality of hESC-derived 
hepatocytes could be improved by making the differentiation method more similar to 
normal in vivo liver development. They show for the first time that stage-specific 
regulation of the WNT/β-catenin pathway results in improved differentiation of 
hESCs to functional hepatocytes. 
 
CANCER 
Role of clock genes in cholangiocarcinoma, long non-coding RNA (lncRNA) in 
hepatocellular carcinoma (HCC) 
Although disruption of circadian rhythm is associated with cancer development and 
progression, little is known on gene regulation of circadian rhythm in 
cholangiocarcinoma. Han et al. investigated the role of period circadian clock 1 (which 
is encoded by Per1 and is a transcriptional repressor that forms a core component of 
the circadian clock) and related microRNAs. They show that disruption of circadian 
rhythms of clock genes, via miR-34a overexpression, contributes to the 
malignant phenotypes of human cholangiocarcinoma. 
Activation of the autocrine interleukin (IL)-6/signal transducer and activator of 
transcription 3 (STAT3) signaling is known to promote liver inflammation and 
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tumorigenesis. Wang et al. show here that low expression of lnc-DILC (for lncRNA 
down-regulated in liver cancer stem cells (LCSCs) markedly enhance LCSC expansion 
via an autocrine activation of IL-6/STAT3 signaling. Mechanistically they found that low 
lnc-DILC levels allowed an increased binding of the transcription factor nuclear factor 
(NF)-κB to IL6 promoter and therefore in increased IL6 induction. This autocrine loop 
may be favored pro-inflammatory cytokines such tumor necrosis α and IL-1β that 
activate NF-κB. Interestingly they found low lnc-DILC levels in livers from patients with 
HCC; moreover, the lower lnc-DILC the poorer the outcome. They suggest that “lnc-
DILC could be not only a potential prognostic biomarker, but also a therapeutic 
target against LCSCs.” 
 
ALCOHOLIC AND NON-ALCOHOLIC STEATOHEPATITIS  
Type 2 diabetes increases the risk of hospitalizations due to chronic liver 
diseases, TRAF1-ASK1 signaling and miR-155 play a crucial role in non-
alcoholic (NASH) and alcoholic steatohepatitis (ASH), respectively 
The impact of type 2 diabetes (T2DM) on hospital admissions and deaths due to 
common chronic liver diseases is uncertain. In a large retrospective study in Scotland, 
Wild et al. found that T2DM is associated with increased risk of hospital admission 
or death for all common chronic liver diseases. In people with T2DM, the most 
common disease was NAFLD, as expected. This study has important public health 
implications since it suggests that increasing prevalence of T2DM is likely to result in 
increasing burden of all chronic liver diseases. 
The molecular mechanisms of NASH and ASH are largely unknown, and translational 
studies are needed to identify novel targets for therapy. Tumor necrosis factor receptor-
associated factor 1 (TRAF1) is an important regulator of inflammation. The role of this 
factor in non-alcoholic steatohepatitis (NASH) is unknown. In this issue, Li et al. 
performed a translational study including human samples and functional studies in 
animal models of NASH. They convincingly demonstrate that TRAF1 functions as a 
positive regulator of insulin resistance, inflammation, and hepatic steatosis in 
NASH, dependent on the activation of ASK1-p38/JNK axis. In another translational 
study, Bala et al. demonstrate a role for the microRNA 155 (miR-155) in ASH. Genetic 
or pharmacological inhibition of miR-155 resulted in increased PPARα (miR-155 
target) binding and decreased cytokine production. Importantly, Kupffer cells 
isolated from miR-155 KO mice exhibited a M2 phenotype, which is less inflammatory. 
4 
 
Finally, miR-155 regulated the induction of fibrogenic genes and collagen 
deposition in several animal models. These results suggest a role for this microRNA 
in ASH and in experimental liver fibrogenesis. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
HCV – a silent killer among young and middle-aged men in Egypt? Viral 
eradication in early HCV cirrhosis normalize life expectancy, DAA treatment 
improves outcome of decompensated hepatitis C 
The majority of people chronically infected with hepatitis C virus (HCV) reside in low- 
and middle-income countries, and with an estimated 10% Egypt has the highest HCV 
prevalence in adults. Excess mortality rate associated with chronic HCV infection was 
evaluated by Mostafa et al. in a community-based cohort study in rural Egypt among 
18,111 survey participants enrolled in 1997-2003 of whom 9.1% were chronically 
infected. Depending on age groups the mortality rate ratios (MRR) in men ranged 
between 2.87 to 2.22, and the all-cause mortality rate attributable to chronic HCV 
infection was 5.7%, while the liver-related mortality was 45.5%. The excess 
mortality described here among young and middle-aged men should be used for 
prioritization of patients in the Egypt National DAA Treatment Programme. 
That the induction of a sustained virologic response (SVR) is associated with an 
improved outcome of chronic hepatitis C virus (HCV) infection, has been demonstrated 
in several studies by comparing patients with and without SVR. The study by Bruno et 
al., however, is the first to demonstrate that patients with compensated cirrhosis 
who achieve SVR will have a life expectancy similar to that of the sex- and age-
matched general population. Included patients were enrolled in historical prospective 
cohort studies from tertiary referral centers from Northern and Southern Italy, 
representative of the Italian general population allowing for adequate comparison of 
patients long-term 10- and 20-year survival with national data. The intriguing 
observations of a trend to worse survival observed in patients with compensated 
cirrhosis Child Class A6 as compared to A5 but also that the incidence of hepatocellular 
carcinoma (HCC) during follow-up after SVR was not negligible, underscore the need 
for early treatment initiation hereby preventing cirrhosis development as the main HCC 
determinant. 
Treatment of decompensated HCV-induced cirrhosis remains challenging even in the 
DAA era and it has to be determined to which extend treatment-induced viral 
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eradication impacts liver function and long-term outcome. In an NHS England 
Expanded Access Programme study by Foster et al. 467 HCV-infected patients with 
decompensated cirrhosis or at risk of irreversible disease were treated for 12 weeks 
with sofosbuvir combined with the NS5A inhibitors ledipasvir or daclatasvir, with or 
without ribavirin. Functional outcome was retrospectively compared to untreated 
patients with decompensated cirrhosis who were registered on the HCV Research UK 
database 6 months before treatment was available. Viral eradication was achieved in 
90.5% and 67% of type 1 and 3 infected patients, respectively, and was associated 
with a significant improvement of the MELD score but also significantly fewer 
treated patients developed a profound worsening in MELD as compared to the 
untreated controls. Although a substantially lower chance of benefit was seen in older 
patients with low albumin or sodium concentrations, the predictive power of these 
parameters were low and they should not be used for making treatment decisions so 
far. 
 
CIRRHOSIS  
Novel biomarker to determine portal pressure response to non-selective beta-
blockers (NSBB)  
Assessment of whether a patient is likely to have a portal pressure response to NSBBs 
requires catheterization of the portal vein. In a very provocative study, Trebicka et al. 
show exciting new data showing for the first time that measuring beta-arrestin-
2, a vasoactive mediator, the expression of which is upregulated in the cirrhotic 
stomach and its levels predict response to NSBBs. If these data can be made more 
quantitative and further validated, it may lead to the development of an important 
decision-making tool to decide on selection of patients for NSBB therapy. 
 
TRANSPLANTATION  
Insights into regulation of rejection and tolerance following liver transplantation  
Although the potential role of Programmed death 1 (PD-1) receptor and its ligand PD-
L1, which are known to fine tune immune responses have been shown to be important 
in maintaining allograft tolerance in animal models, their role is unknown in humans. 
Shi et al. provide the first indication that the interplay between donor PD-L1 and 
recipient PD-1, are also involved in the counter regulation of allograft rejection 
and may therefore be a potential target for inducing tolerization. 
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CHOLESTASIS  
CFTR correctors can rescue defective plasma membrane ATP8B1 and is a 
potential novel therapeutic approach  
Treatment options for familial intrahepatic cholestasis are limited with many patients 
needing liver transplantation as the only therapeutic option. A very important paper 
by van der Woerd et al. shows that the plasma membrane defect of ATP8B1 
mutation that results in protein misfolding can be corrected using the known 
correctors of cystic fibrosis conductance regulator (CFTR) gene mutation in 
vitro. If this in vitro observation can be confirmed in vivo, a new therapeutic for this 
type of diseases may emerge as the correctors of CFTR are already clinically available.  
 
HEPATOCYTE TRANSPLANTATION  
Biliary fibrosis induces proliferation of transplanted hepatocytes and phenotype 
switch  
The clinical application of hepatocyte transplantation has been limited by the ability of 
the transplant cells to populate the recipient liver. Many lines of investigation provide 
evidence that liver injury provides a stimulus for liver repopulation with the transplanted 
cells. The paper by Yovchev et al. provides important new data that inducing 
biliary fibrosis is associated with increased ability of the transplanted 
hepatocytes to proliferate, and start to express biliary markers. They suggest that 
these effects may be mediated by osteopontin, providing a potentially translatable 
strategy. 
